Voyager Therapeutics, Inc.
VYGR
$4.46
-$0.42-8.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -49.53% | -80.88% | -70.38% | -43.75% | -68.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -49.53% | -80.88% | -70.38% | -43.75% | -68.00% |
| Cost of Revenue | 5.93% | 16.75% | 16.28% | 28.41% | 35.47% |
| Gross Profit | -104.83% | -311.29% | -360.07% | -439.79% | -128.43% |
| SG&A Expenses | 1.46% | 0.15% | 0.10% | 4.38% | 0.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.93% | 12.69% | 12.21% | 22.16% | 25.62% |
| Operating Income | -58.87% | -1,311.33% | -2,871.99% | -482.28% | -166.21% |
| Income Before Tax | -85.86% | -570.68% | -1,205.04% | -3,511.56% | -148.11% |
| Income Tax Expenses | -78.35% | -20.38% | -0.59% | -4.18% | -52.77% |
| Earnings from Continuing Operations | -84.18% | -589.88% | -1,296.21% | -2,682.29% | -149.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.18% | -589.88% | -1,296.21% | -2,682.29% | -149.12% |
| EBIT | -58.87% | -1,311.33% | -2,871.99% | -482.28% | -166.21% |
| EBITDA | -63.41% | -918.94% | -16,744.55% | -658.53% | -160.14% |
| EPS Basic | -81.30% | -388.61% | -683.06% | -8,479.41% | -134.79% |
| Normalized Basic EPS | -84.84% | -364.67% | -589.20% | -175,320.00% | -132.76% |
| EPS Diluted | -79.83% | -404.48% | -756.10% | -3,033.05% | -136.79% |
| Normalized Diluted EPS | -84.84% | -375.32% | -633.94% | -4,242.08% | -134.26% |
| Average Basic Shares Outstanding | 1.77% | 7.90% | 14.88% | 23.03% | 34.11% |
| Average Diluted Shares Outstanding | 1.77% | 7.36% | 14.26% | 22.32% | 32.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |